Press "Enter" to skip to content

Alpha Emitter Market Outlook 2019 | Shows Industry Overview, Size, Share, Remarkable Growth Factors, Types, and Applications Forecast to 2024


The “Alpha Emitter Market” research report 2019 delivers comprehensive information about the market ranging from the establishment to the predictable growth trend. Alpha Emitter market report provides brief analytical data of the market contenders globally using advanced methodological approaches, such as SWOT analysis, production chain, cost, sales margin, financial details, recent developments. Alpha Emitter market report also offers market competitors that includes detailed company profiles along with company product specifications.

Market Overview:

  • The global alpha emitter market was valued at USD 506.5 million in 2018, and it is estimated to be valued at USD 3302.99 million by 2024 while witnessing a CAGR of 36.69% over the forecast period of 2019-2024. Certain factors that are driving the market growth include increased awareness about the potential benefits of targeted alpha therapy, and the growing number of patients with cardiac and cancer ailments.
  • Targeted anticancer or alpha therapy (TAT) is gaining popularity with the increasing prevalence of cancer and cardiovascular diseases. Consumers are now increasingly aware of the potential benefits of targeted therapies to cure such ailments.
  • Furthermore, radioimmunotherapy with short-ranged and high-efficiency α-particles is a striking and promising treatment approach. α-particles have an advantage in targeted therapy because of their exceptionally high cell-killing ability.
  • However, regulatory requirements pose a hurdle to translational research and clinical investigations. For instance, in the United States, all pharmacologic agents, including diagnostic radiopharmaceuticals and radiotherapeutics, undergo regulatory oversight by the FDA. Similarly, radiopharmaceuticals face additional scrutiny and undergo unique regulatory and approval pathways, across the world.
  • Get a Sample Copy of the Report –

    In Alpha Emitter Market Report, Following Companies Are Covered:

  • Actinium Pharmaceutical Inc.
  • Alpha Tau Medical Ltd
  • Bayer AG
  • Fusion Pharmaceuticals
  • IBA Radiopharma Solutions
  • RadioMedix Inc.
  • Telix Pharmaceuticals Ltd

    Alpha Emitter Market 2019 report will help the industry aspirants in arranging their strategies. The measurements offered in this report will be an exact and helpful manual to shape the business development. Additionally, will Provide historical data along with a future forecast and detailed analysis and also expected opportunities.

    Scope of the Report:

  • In therapeutic radiopharmaceuticals, radionuclides with alpha emitters play a significant role in treating cancers. Properties of alpha emitters have led to exert profound differences between this field and other fields of nuclear medicine. Due to their short range and high LET (deposit energy in a unit length of their pathway), alpha particles have remarkably been considered into medical research.

    Reasons for Buying Alpha Emitter Market Report:

    • This report provides pin-point analysis for changing competitive dynamics
    • It provides a forward looking perspective on different factors driving or restraining market growth
    • It provides a five-year forecast assessed on the basis of how the market is predicted to grow
    • It helps in understanding the key product segments and their future
    • It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
    • It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

    For More Information or Query or Customization Before Buying, Visit at –

    Key Market Trends:

    Medical Application in Ovarian Cancer is Expected to Observe the Highest Growth Rate over the Forecast Period

    The ovarian cancer segment in the alpha emitter market is expected to witness the highest CAGR of 35.63% during the forecast period.

    The growth rate is attributed to an increasing number of new diagnosis cases. As per the estimates of the American Cancer Society, in 2018, around 22,240 women were expected to receive a new diagnosis of ovarian cancer, and about 14,070 women would die from ovarian cancer.

    Ovarian cancer uses radioimmunotherapy as locally injected adjuvant therapy. Trials have evaluated the practice of complete abdominal or moving-strip external-beam radiotherapy (EBRT) or non-specific i.p. radiotherapy, with colloid preparations of Au-198 or P-32 as adjuvant therapies.

    Moreover, the adoption of targeted alpha therapy with higher LET and shorter wavelengths has been promising in the treatment process. This trend is expected to gain traction in the near future.

    In addition, a recent Phase I clinical trial involving At-211-MX35 F (ab′) showed significant efficacy, as therapeutic doses reached their targets in patients with ovarian cancer.

    North America Dominates the Market and is Expected to do Same in the Forecast Period

    North America currently dominates the alpha emitter market, and it is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future, owing to the fact that the increase in cardiac and neurological chronic diseases is the major driving factor for the market growth in the region. For instance, 223RaCl2 (Xofigo) is the first alpha-emitting radioisotope to gain registration in the United States for palliative therapy of prostate cancer bone metastases through indirect physiological targeting.

    Moreover, according to the National Cancer Institute, the number of new cases of melanoma was 21.8 per 100,000 men and women, per year. Similarly, the rising prevalence of cancer is making it imperative for the healthcare professionals across Canada to increase the radiotherapy utilization for cancer treatment. This is directly affecting the growth of the alpha emitter market in the country.

    The Research Document Will Answer Following Questions Such as:

    • What are the cutting-edge technologies responsible for driving the growth of the market?
    • What are the main applications of the market? What are the growth prospects to the market applications into the market?
    • At what stage of development are the key market products?
    • What are the shortcomings that has to face to become commercially viable? Is their growth and commercialization dependent on cost declines or technological/application breakthroughs?
    • What is the outlook for the industry?
    • What difference does performance characteristics of Alpha Emitter create from those of established entities?

    Purchase this Report (Price 4250 USD for single user license) –

    Detailed TOC of Alpha Emitter Market Report 2019-2024:

    1.1 Study Deliverables
    1.2 Study Assumptions
    1.3 Scope of the Study



    4.1 Market Overview
    4.2 Market Drivers
    4.2.1 Increased Awareness About the Potential Benefits of Targeted Alpha Therapy
    4.2.2 Increasing Number of Patients with Cardiac and Cancer Ailments
    4.3 Market Restraints
    4.3.1 Short Half-life of Radiopharmaceuticals
    4.3.2 Stringent Regulatory Framework and Reimbursement Issues
    4.3.3 Need for High Capital Investment
    4.4 Porter’s Five Forces Analysis
    4.4.1 Threat of New Entrants
    4.4.2 Bargaining Power of Buyers/Consumers
    4.4.3 Bargaining Power of Suppliers
    4.4.4 Threat of Substitute Products
    4.4.5 Intensity of Competitive Rivalry

    5.1 Type of Radionuclide
    5.1.1 Terbium (Tb-149)
    5.1.2 Astatine (At-211)
    5.1.3 Bismuth (Bi-212)
    5.1.4 Actinium (Ac-225)
    5.1.5 Radium (Ra-223)
    5.1.6 Lead (Pb-212)
    5.1.7 Bismuth (Bi -213)
    5.2 Medical Application
    5.2.1 Glioma
    5.2.2 Melanoma
    5.2.3 Pancreatic Cancer
    5.2.4 Ovarian Cancer
    5.2.5 Thyroid
    5.2.6 Bone Metastasis
    5.2.7 Lymphoma
    5.2.8 Endocrine Tumors
    5.2.9 Other Medical Applications
    5.3 Geography
    5.3.1 North America United States Canada Mexico
    5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
    5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
    5.3.4 Middle East & Africa GCC South Africa Rest of Middle East & Africa
    5.3.5 South America Brazil Argentina Rest of South America

    6.1 Company Profiles
    6.1.1 Actinium Pharmaceutical Inc.
    6.1.2 Alpha Tau Medical Ltd
    6.1.3 Bayer AG
    6.1.4 Fusion Pharmaceuticals
    6.1.5 IBA Radiopharma Solutions
    6.1.6 RadioMedix Inc.
    6.1.7 Telix Pharmaceuticals Ltd



    Contact Us:

    Name: Ajay More

    Phone: US +14242530807/ UK +44 20 3239 8187

    Email: [email protected]

    Our Other Reports:

    Hybrid Operating Rooms Market Share, Size 2019 Growing Rapidly with Modern Trends, Development, Revenue, Demand and Forecast to 2024 | Says Industry Research Biz

    Acrolein [Acraldehyde] Market 2019 Industry Business Challenges, Share, Geographical Segmentation, Consumption Status and Opportunity Analysis: World Market Outlook to 2024

    Global Urological Catheters Market 2019 in-Depth Analysis by Market Size, Share, Key Players, and Regions, Business Expansion Plans Covered Forecast till 2025

    Sports Tourism Market Size 2019 – Global Share, Leading Company Analysis, Research Methodology, Current and Future Plans by Forecast to 2023